Home/ Stocks/ VRAX

Virax Biolabs Group Limited Ordinary Shares

VRAX XNAS

$3.18 +0.67 (+24.28%) ▲ 15-min delayed

Open

$3.24

High

$4.29

Low

$2.81

Volume

18.13M

Market Cap

$2.20M

About Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Employees: 26 Website →

TickerDaily Coverage

Stock Market Today, July 10, 2026: Weekly Recap of Extreme Movers — VRAX, GMM Lead Volatility Surge

Market News David Brooks · Jul 10, 2026

The stock market delivered extreme volatility this week, with micro-cap and biotech stocks leading...

Why Is Virax Biolabs Group Limited Ordinary Shares (VRAX) Stock Up 246.5% Today?

Penny Stocks Marcus Rivera · Jul 9, 2026

Virax Biolabs Group Limited (VRAX) is experiencing a rare explosive move, jumping 246.5% to $11.08...

Why Is Virax Biolabs Group Limited Ordinary Shares (VRAX) Stock Up 54.9% Today?

Penny Stocks Marcus Rivera · Mar 31, 2026

Virax Biolabs Group Limited (VRAX) stock ripped 54.9% higher on Tuesday, March 31, 2026, after...

View All Coverage →

Get VRAX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Virax Biolabs Group Limited Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.